Emodepside Clinical Trials

Size	Price	Qty
5mg	USD 217
25mg	USD 667

Clinical Trials

Multiple clinical trials across Phase 1, Phase 2, and Phase 3 evaluate emodepside to establish its safety, efficacy, and pharmacokinetics in healthy volunteers and patients with neglected tropical parasitic diseases, including strongyloidiasis, hookworm, Trichuris trichiura, Ascaris lumbricoides, filariasis, and onchocerciasis. Key sponsors driving these evaluations include the Swiss Tropical and Public Health Institute, the Drugs for Neglected Diseases initiative, Bayer, and the Bill & Melinda Gates Foundation. With recruitment statuses ranging from not yet recruiting to active and completed, these studies aim to advance nematode therapeutics.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06800248	NOT_YET_RECRUITING	Trichuris Trichiura; Infection; Hookworm Infection; Ascaris Lumbricoides Infection	Swiss Tropical & Public Health Institute	2026-11-06	PHASE3
NCT07258173	NOT_YET_RECRUITING	Trichuris Infection	Jennifer Keiser	2026-11-15	PHASE2
NCT05180461	ACTIVE_NOT_RECRUITING	Onchocerciasis	Drugs for Neglected Diseases	2021-08-30	PHASE2
NCT06736691	ACTIVE_NOT_RECRUITING	Trichuris Trichiura; Infection; Hookworm Infection; Ascaris Lumbricoides Infection	Swiss Tropical & Public Health Institute	2025-11-25	PHASE3
NCT06373835	COMPLETED	Strongyloides Stercoralis Infection; Strongyloidiasis	Swiss Tropical & Public Health Institute	2024-05-20	PHASE2
NCT06412926	COMPLETED	Soil-transmitted Helminth Infection; Onchocerciasis (River Blindness)	Bayer	2024-05-07	PHASE1
NCT06373835	Not yet recruiting	Strongyloides Stercoralis Infection\|Strongyloidiasis	Swiss Tropical & Public Health Institute\|National Institute of Public Health Vientiane Laos	2024-05-01	Phase 2
NCT05538767	COMPLETED	Hookworm Infections	Jennifer Keiser	2022-09-16	PHASE2
NCT05538767	Completed	Hookworm Infections	Jennifer Keiser\|Public Health Laboratory Ivo de Carneri\|Swiss Tropical & Public Health Institute	2022-09-16	Phase 2
NCT05017194	COMPLETED	Trichuris Trichiura; Infection; Hookworm Infections	Jennifer Keiser	2021-08-02	PHASE2
NCT05017194	Completed	Trichuris Trichiura; Infection\|Hookworm Infections	Jennifer Keiser\|Public Health Laboratory Ivo de Carneri\|Swiss Tropical & Public Health Institute	2021-08-02	Phase 2
NCT03383614	COMPLETED	Filariasis	Drugs for Neglected Diseases	2017-11-14	PHASE1
NCT03383523	COMPLETED	Filariasis	Drugs for Neglected Diseases	2017-10-26	PHASE1
NCT03383614	Completed	Filariasis	Drugs for Neglected Diseases\|Bayer\|Bill and Melinda Gates Foundation	2017-11-14	Phase 1
NCT03383523	Completed	Filariasis	Drugs for Neglected Diseases\|Bayer\|Bill and Melinda Gates Foundation	2017-10-26	Phase 1
NCT02661178	COMPLETED	Healthy Volunteers	Drugs for Neglected Diseases	2015-12	PHASE1
NCT02661178	Completed	Healthy Volunteers	Drugs for Neglected Diseases\|Bayer\|Bill and Melinda Gates Foundation	2015-12	Phase 1

(data from https://clinicaltrials.gov, updated on 2026-08-14)

Check the Emodepside product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Emodepside selectively binds to and activates calcium-dependent SLO-1-like potassium channels in parasitic nematodes, inducing hyperpolarization of neuromuscular cell membranes and blocking pharyngeal pumping and somatic movement. This neuromuscular paralysis prevents nutrient uptake and parasite locomotion, directly driving anthelmintic efficacy in clinical indications such as strongyloidiasis, hookworm infections, filariasis, and onchocerciasis.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).